ACTs are the mainstay of recommended treatment for P. falciparum malaria and, as no alternative to artemisinin derivatives is expected to enter the market for at least several years, their efficacy must be preserved. WHO recommends that national malaria control programmes regularly monitor the efficacy of antimalarial medicines in use to ensure that the chosen treatments remain efficacious.